产品名称 | NebuSelect™ Recombinant Human CLEC4A/DCIR, hFc-tag |
---|---|
目录号 | NBL-242806 |
别名 | CLEC4A/DCIR; CD367; Clec4a2; CLECSF6; DCIR; DDB27; HDCGC13P; LLIR; CLEC4A; DCIRLLIR |
外观 | see COA |
分子量 | |
CAS | N/A |
溶解度 | Water Soluble |
存储条件 | Short term 4℃; Long term -20℃. |
保存时间 | 2 years |
备注1 | Q9UMR7-1 |
备注2 |
目录号 | 规格 | 价格 | 库存状态 | |
NBL-242806-100ug | 100ug | Inquire | Inquire | |
NBL-242806-1mg | 1mg | Inquire | Inquire | |
NBL-242806-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Human CLEC4A/DCIR, hFc-tag
Catalog#:
NBL-242806
Description:
NebuSelect™ Recombinant Human CLEC4A/DCIR, hFc-tag(Cat#NBL-242806) is expressed in HEK293 with hFc tag at the C-Terminus.It contains Gln70-Leu237.
Species:
Human
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 46.7 kDa. Due to glycosylation, the protein migrates to 60-65 kDa based on Bis-Tris PAGE result.
Target Name:
CLEC4A/DCIR; CD367; Clec4a2; CLECSF6; DCIR; DDB27; HDCGC13P; LLIR; CLEC4A; DCIRLLIR
Target Information:
Clec4a has been reported to be an immune suppressor of dendritic cells (DCs), but its potential role in cancer therapy remains to be elucidated. silencing of Clec4a2 expression via skin delivery of shRNA produces an effective antitumor response and that Clec4a2 shRNA may have therapeutic potential as an adjuvant for cancer immunotherapy.
Amino Acid Sequence:
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.